{"product_id":"nsj-v9437-100ug-100ug","title":"Recombinant CD30 Antibody, 100 ug","description":"\u003cp\u003eRecognizes a single chain glycoprotein of 105\/120kDa, identified as CD30\/Ki-1. Its epitope is located somewhere between aa 580-595 (cytoplasmic). CD30 is synthesized as a 90kDa precursor, which is processed in the Golgi complex into a membrane-bound phosphorylated mature 105\/120kDa glycoprotein. In Hodgkin s disease, CD30\/Ki-1 antigen is expressed by mononuclear-Hodgkin and multinucleated Reed-Sternberg cells. It is also expressed by the tumor cells of a majority of anaplastic large cell lymphomas as well as by a varying proportion of activated T and B cells. This MAb distinguishes large cell lymphomas derived from activated lymphoid cells from histiocytic malignancies and lymphomas derived from resting and precursor lymphoid cells or from anaplastic carcinomas. About one third of the Ki-1 positive lymphomas lack the leukocyte common antigen (CD45).\u003c\/p\u003e\u003ch3\u003eSpecifications\u003c\/h3\u003e\u003ctable style=\"width:100%; border-collapse:collapse;\"\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eCatalog No\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003eV9437-100UG\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eFamily\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003ePrimary antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eQty\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003e100 ug\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eFormulation\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003e0.2 mg\/ml in 1X PBS with 0.1 mg\/ml BSA (US sourced), 0.05% sodium azide\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eFormat\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003ePurified\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eClone\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003erKi-1\/6913\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eHost Animal\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003eMouse\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eClonality\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003eRecombinant Mouse Monoclonal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eIsotype\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003eMouse IgG1, kappa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eSpecies Reactivity\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eApplication\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003eIHC-P\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eApplication Details\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003eImmunohistochemistry (FFPE): 1-2ug\/ml\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eApplication Note\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003eOptimal dilution of the recombinant CD30 antibody should be determined by the researcher.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eLocalization\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003eCell Surface\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eImmunogen\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003eA portion of amino acids 495-595 was used as the immunogen for the recombinant CD30 antibody.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003ePurity\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003eProtein A affinity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eStorage\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003eAliquot the recombinant CD30 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eLimitation\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003eThis recombinant CD30 antibody is available for research use only.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eUniprot #\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003eP28908\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eStatus\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003eAvailable\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003ePDF Link\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003e\u003ca href=\"https:\/\/www.nsjbio.com\/tds-pdf\/recombinant-cd30-antibody-rki-16913-v9437\" target=\"_blank\" rel=\"noopener noreferrer\"\u003ehttps:\/\/www.nsjbio.com\/tds-pdf\/recombinant-cd30-antibody-rki-16913-v9437\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eTitle\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003eRecombinant CD30 Antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eDescription\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003eRecognizes a single chain glycoprotein of 105\/120kDa, identified as CD30\/Ki-1. Its epitope is located somewhere between aa 580-595 (cytoplasmic). CD30 is synthesized as a 90kDa precursor, which is processed in the Golgi complex into a membrane-bound phosphorylated mature 105\/120kDa glycoprotein. In Hodgkin s disease, CD30\/Ki-1 antigen is expressed by mononuclear-Hodgkin and multinucleated Reed-Sternberg cells. It is also expressed by the tumor cells of a majority of anaplastic large cell lymphomas as well as by a varying proportion of activated T and B cells. This MAb distinguishes large cell lymphomas derived from activated lymphoid cells from histiocytic malignancies and lymphomas derived from resting and precursor lymphoid cells or from anaplastic carcinomas. About one third of the Ki-1 positive lymphomas lack the leukocyte common antigen (CD45).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e","brand":"NSJ Bioreagents","offers":[{"title":"100 ug","offer_id":51544882479384,"sku":"V9437-100UG","price":559.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0590\/5652\/1400\/files\/get_image_0741b352-d008-433b-9746-fca862a8933a.jpg?v=1768193385","url":"https:\/\/danabiosci.com\/products\/nsj-v9437-100ug-100ug","provider":"Dana Bioscience","version":"1.0","type":"link"}